Basket cover image
16 handpicked stocks

Fortress America: Insulated From Trade Wars

Puma's recent profit warning, driven by U.S. tariffs, highlights the significant financial risks associated with global trade disputes. This event underscores a potential investment opportunity in companies with primarily domestic supply chains that are better insulated from such geopolitical volatility.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 25

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

TSCO

Tractor Supply Company

TSCO

Current price

$62.28

XPO

XPO Inc.

XPO

Current price

$131.44

CSL

Carlisle Companies Incorporated

CSL

Current price

$386.92

About This Group of Stocks

1

Our Expert Thinking

Recent events like Puma's tariff-driven profit warning highlight the risks facing companies with global supply chains. We've identified businesses with predominantly domestic operations that may offer greater stability during trade disputes and geopolitical tensions.

2

What You Need to Know

This group focuses on companies operating primarily within U.S. borders, spanning domestic logistics, construction materials, and U.S.-based manufacturing. These businesses face reduced exposure to import duties and international shipping complexities that can impact earnings.

3

Why These Stocks

Each company was handpicked by professional analysts for their defensive positioning against tariff-related market shocks. Their operational structures offer potential insulation from the headline risks affecting globally-oriented firms, making them tactical portfolio additions.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+7.57%

Group Performance Snapshot

7.57%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 7.57% over the next year.

10 of 16

Stocks Rated Buy by Analysts

10 of 16 assets in this group are rated Buy by professional analysts.

4.2% vs 4%

Group Growth vs Bank interest

This group averaged a 4.2% return last month, beating the typical 4% bank rate.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🛡️

Trade War Protection

While global companies face tariff headwinds, these domestic-focused businesses offer potential shelter from international trade disputes that can devastate earnings overnight.

🏭

Made in America Advantage

Companies with U.S.-based supply chains are positioned to benefit from reshoring trends and avoid the supply chain disruptions that plague internationally dependent competitors.

📈

Stability in Uncertainty

When headlines about trade wars send global stocks tumbling, these domestically insulated companies may offer the earnings predictability that investors crave during volatile times.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.